JNCEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (4 5月 2023 @ 05:00):

Stats
本日の出来高	11.60M
平均出来高	3.47M
時価総額	98.95M
EPS	$0 ( 2024-03-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.958
ATR14	$0.0820 (4.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-03	Concentra Biosciences, Llc	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Sell	5 300 087	Common Stock
2023-05-03	Concentra Biosciences, Llc	Buy	0	Common Stock
2023-05-03	Salter-cid Luisa	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-96.60
Last 98 transactions
Buy: 1 025 987 \| Sell: 8 913 091

ボリューム相関

長: -0.01 (neutral)

短: -0.19 (neutral)

Signal:(59.515) Neutral

Jounce Therapeutics Inc 相関

10 最も正の相関
SVAC	0.941
BLPH	0.916
TZPSU	0.914
TZPS	0.913
ARRW	0.911
NBST	0.909
EBACU	0.908
MTSL	0.908
ARDX	0.903
KBAL	0.902

10 最も負の相関
LWAC	-0.964
FRBA	-0.956
AMAL	-0.953
CCB	-0.953
CVBF	-0.95
RBB	-0.946
FBMS	-0.946
MYFW	-0.944
INDB	-0.942
CBAN	-0.941

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Jounce Therapeutics Inc 相関 - 通貨/商品

0.01
( neutral )

0.71
( moderate )

0.00
( neutral )

0.36
( neutral )

0.75
( moderate )

0.03
( neutral )

Jounce Therapeutics Inc 財務諸表

Annual	2022
収益:	$82.00M
総利益:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2022
収益:	$82.00M
総利益:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2021
収益:	$26 907.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00182

FY	2020
収益:	$62.34M
総利益:	$62 339.00 (0.10 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.